The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Type I interferons in infectious disease
Open accessAbstract
Type I interferons (IFNs) have diverse effects on innate and adaptive immune cells during infection with viruses, bacteria, parasites and fungi, directly and/or indirectly through the induction of other mediators. Type I IFNs are important for host defence against viruses. However, recently, they have been shown to cause immunopathology in some acute viral infections, such as influenza virus infection. Conversely, they can lead to immunosuppression during chronic viral infections, such as lymphocytic choriomeningitis virus infection. During bacterial infections, low levels of type I IFNs may be required at an early stage, to initiate cell-mediated immune responses. High concentrations of type I IFNs may block B cell responses or lead to the production of immunosuppressive molecules, and such concentrations also reduce the responsiveness of macrophages to activation by IFNγ, as has been shown for infections with Listeria monocytogenes and Mycobacterium tuberculosis. Recent studies in experimental models of tuberculosis have demonstrated that prostaglandin E2 and interleukin-1 inhibit type I IFN expression and its downstream effects, demonstrating that a cross-regulatory network of cytokines operates during infectious diseases to provide protection with minimum damage to the host.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“If type I IFNs are present early and properly localized to sites of infection, they can effectively limit viral propagation, as type I IFNs are responsible for optimal activation of macrophages, antigen presentation by DCs, and enhanced anti-viral effector T cell responses106.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [106]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets
Gerold, G., & Pietschmann, T. (2014) · Digestive Diseases · doi:10.1159/000360830 · Cited by 4,871
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Ge, D., Fellay, J., Thompson, A. J. V., Simon, J. S., Shianna, K. V., Urban, T. J., Heinzen, E. L., Qiu, P., Bertelsen, A. H., Muir, A. J., et al. (2009) · Nature · doi:10.1038/nature08309 · Cited by 3,533
Regulation of type I interferon responses
Ivashkiv, L. B., & Donlin, L. T. (2013) · Nature reviews. Immunology · doi:10.1038/nri3581 · Cited by 3,442
Functional Role of Type I and Type II Interferons in Antiviral Defense
Müller, U., Steinhoff, U., Reis, L. F. L., Hemmi, S., Pavlovic, J., Zinkernagel, R. M., & Aguet, M. (1994) · Science · doi:10.1126/science.8009221 · Cited by 2,453
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus
Thomas, D. L., Thio, C. L., Martin, M. P., Qi, Y., Ge, D., Ó’hUigín, C., Kidd, J. R., Kídd, K. K., Khakoo, S. I., Alexander, G., et al. (2009) · Nature · doi:10.1038/nature08463 · Cited by 2,147
Tanaka, Y., Nishida, N., Sugiyama, M., Kurosaki, M., Matsuura, K., Sakamoto, N., Nakagawa, M., Korenaga, M., Hino, K., Hige, S., et al. (2009) · Nature Genetics · doi:10.1038/ng.449 · Cited by 2,141
An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis
Berry, M. P. R., Graham, C. M., McNab, F. W., Xu, Z., Bloch, S. A. A., Oni, T., Wilkinson, K. A., Banchereau, R., Skinner, J., Wilkinson, R. J., et al. (2010) · Nature · doi:10.1038/nature09247 · Cited by 1,898
Self-citationInterferons, interferon‐like cytokines, and their receptors
Pestka, S., Krause, C. D., & Walter, M. R. (2004) · Immunological Reviews · doi:10.1111/j.0105-2896.2004.00204.x · Cited by 1,845
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Study, F. T. H. C., Suppiah, V., Moldovan, M. V., Ahlenstiel, G., Berg, T., Weltman, M., Abate, M. L., Bassendine, M. F., Spengler, U., Dore, G. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.447 · Cited by 1,829
Cited by
Sorted by citations
Items 1,001–1,004 of 1,004
Seyedmousavi, S., Davis, M. J., Sugui, J. A., Pinkhasov, T., Moyer, S., Salazar, A. M., Chang, Y. C., & Kwon-Chung, K. J. (2018) · mBio · doi:10.1128/mbio.00422-18 · Cited by 17
Wang, Y., Feng, H., Li, X., Ruan, Y., Guo, Y., Cui, X., Zhang, P., Li, Y., Wang, X., Wang, X., et al. (2024) · PLOS Pathogens · doi:10.1371/journal.ppat.1012230 · Cited by 7
Lok, S., Lau, T. N. H., Trost, B., Tong, A. H. Y., Wintle, R. F., Engstrom, M. D., Stacy, E., Waits, L. P., Scrafford, M., & Scherer, S. W. (2022) · G3 Genes|Genomes|Genetics · doi:10.1093/g3journal/jkac138 · Cited by 6
Lok, S., Lau, T. N. H., Trost, B., Tong, A. H. Y., Paton, T., Wintle, R. F., Engstrom, M. D., Gunn, A., & Scherer, S. W. (2024) · Scientific Reports · doi:10.1038/s41598-024-67270-9 · Cited by 4
Metadata
- Authors
- McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A.
- Affiliations
- GlaxoSmithKline (United Kingdom) (GB)
- National Institutes of Health (US)
- National Institute for Medical Research (GB)
- Venue
- Nature Reviews Immunology
- Published
- 2015-01-23
- Volume
- 15
- Issue
- 2
- Pages
- 87-103
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7162685
- OpenAlex
- W2091129202
- Cited by
- 2,780
- References
- 238
- Citations by year
- 2026: 263 · 2025: 333 · 2024: 364 · 2023: 330 · 2022: 330 · 2021: 307 · 2020: 194 · 2019: 160 · 2018: 166 · 2017: 169 · 2016: 119 · 2015: 44
- FWCI
- 15.67
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (FC001126)
- Francis Crick Institute (10206, 10126)
- Cancer Research UK (FC001126)
- National Institutes of Health
- Medical Research Council (U117597139, U117565642)
- National Institute of Allergy and Infectious Diseases
- FP7 Ideas: European Research Council (294682)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Immune Response and Inflammation
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- type I interferon, innate immunity, viral infection, bacterial infection, parasitic infection, fungal infection, immunopathology, influenza virus, lymphocytic choriomeningitis virus, chronic viral infection, immunosuppression, B cell response, macrophage activation, Listeria monocytogenes, Mycobacterium tuberculosis, prostaglandin E2, interleukin-1, host defense
- MeSH terms
- Animals, Bacterial Infections, Communicable Diseases, Humans, Interferon Type I, Mycoses, Parasitic Diseases, Virus Diseases, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
